肠道菌群介导霉酚酸药代动力学与肾移植个体化给药
该研究在84例肾移植受者中结合群体药代动力学建模与粪便宏基因组测序,发现5种细菌与霉酚酸(MPA)肠肝循环的幅度或持续时间相关。高丰度Eubacterium callanderi使MPA暴露增加29-63%而需降低MMF剂量17%,高丰度Faecalibacterium SGB15315使暴露降低13-26%而需提高剂量50-75%。
要点
- Eubacterium callanderi高丰度者MPA暴露增加29-63%,建议MMF剂量降低17%
- Faecalibacterium SGB15315高丰度者MPA暴露降低13-26%,需提高剂量50-75%
- 上述两种菌可能识别需加强治疗药物监测或调整剂量的患者
核心结论
- 鉴定出多种影响MPA药代动力学的粪便微生物物种。
- Eubacterium callanderi与Faecalibacterium SGB15315可能识别需额外治疗药物监测或剂量调整以达到目标浓度的患者。
研究设计与样本
- 在84例肾移植受者中,用NONMEM®建立MPA及其葡糖苷酸代谢物的群体药代动力学模型。
- 药代采样后2天内采集粪便行鸟枪法宏基因组测序,并用机器学习识别与药代变异相关的微生物物种。
- 采用全固定效应建模评估微生物物种与临床协变量的影响,并模拟不同MMF剂量下微生物相对丰度对MPA治疗目标达成的影响。
主要发现
- 5种细菌与肠肝循环(EHC)的幅度或持续时间相关。
- Eubacterium callanderi高相对丰度增加EHC,使MPA暴露增加29-63%。
- Faecalibacterium SGB15315高相对丰度降低EHC,使MPA暴露降低13-26%。
- Gemmiger formicilis与Eisenbergiella tayi使EHC延长>100%,Anaerostipes caccae使EHC降低30%,但这些分类群未临床影响治疗目标达成。
关键数值与推荐
- Eubacterium callanderi高丰度需将MMF剂量降低17%。
- Faecalibacterium SGB15315高丰度需将MMF剂量提高50-75%。
- Gemmiger formicilis与Eisenbergiella tayi使EHC延长>100%,Anaerostipes caccae使EHC降低30%。
临床怎么用
- 对Eubacterium callanderi或Faecalibacterium SGB15315高丰度患者加强治疗药物监测。
- 依据微生物相对丰度考虑MMF剂量调整以达MPA治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The gut microbiome contributes to interindividual variability in drug pharmacokinetics; however, its role in guiding dose adjustments remains unclear. Mycophenolic acid (MPA), the active metabolite of the immunosuppressant mycophenolate mofetil (MMF), exhibits high pharmacokinetic variability, potentially linked to microbial activity. This study aimed to characterize the gut microbiome effect on MPA pharmacokinetics and determine if these effects necessitate dose modifications. METHODS: In 84 kidney transplant recipients, plasma and urine concentration-time profiles for MPA and its glucuronide metabolites were characterized using population pharmacokinetic modeling in NONMEM®. Stool samples were collected within 2 days of pharmacokinetic sampling for microbiome shotgun metagenomic sequencing. Machine learning was used to identify microbial species associated with pharmacokinetic variability. The impact of these species and clinical covariates was evaluated using full fixed-effect modeling. Simulations were conducted to assess the effect of microbial relative abundance on MPA therapeutic target attainment across various MMF doses. RESULTS: Five bacteria were associated with the magnitude or duration of enterohepatic circulation (EHC). High relative abundance of Eubacterium callanderi increased EHC and MPA exposure by 29-63%, requiring a 17% lower MMF dose. Conversely, high Faecalibacterium SGB15315 abundance reduced EHC and MPA exposure by 13-26%, requiring a 50-75% higher dose. While Gemmiger formicilis and Eisenbergiella tayi prolonged EHC by >100% and Anaerostipes caccae decreased it by 30%, these taxa did not clinically impact therapeutic target attainment. CONCLUSION: We identified several stool microbial species affecting MPA pharmacokinetics. Specifically, Eubacterium callanderi and Faecalibacterium SGB15315 may identify patients who require additional therapeutic drug monitoring or possible dose modifications to reach target concentrations. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT04953715.
引用
- Saqr, Mohamed, Staley, et al. Microbiome-Mediated Pharmacokinetics and Informed Dosing of Mycophenolate in Kidney Transplantation. Clin Pharmacokinet. 2026. PMID: 42955188. doi:10.1007/s40262-026-01707-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。